Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Gains from Sales and Divestitures (2017 - 2024)

Historic Gains from Sales and Divestitures for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q4 2024 value amounting to $581346.0.

  • Rhythm Pharmaceuticals' Gains from Sales and Divestitures rose 17059.86% to $581346.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $581346.0, marking a year-over-year increase of 17059.86%. This contributed to the annual value of $581346.0 for FY2024, which is 17059.86% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $581346.0 for Q4 2024, which was up 17059.86% from $214837.0 recorded in Q4 2023.
  • In the past 5 years, Rhythm Pharmaceuticals' Gains from Sales and Divestitures ranged from a high of $581346.0 in Q4 2024 and a low of $27583.0 during Q4 2021
  • Over the past 4 years, Rhythm Pharmaceuticals' median Gains from Sales and Divestitures value was $186691.5 (recorded in 2022), while the average stood at $245578.0.
  • In the last 5 years, Rhythm Pharmaceuticals' Gains from Sales and Divestitures surged by 47479.61% in 2022 and then surged by 3550.45% in 2023.
  • Over the past 4 years, Rhythm Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $27583.0 in 2021, then skyrocketed by 474.8% to $158546.0 in 2022, then surged by 35.5% to $214837.0 in 2023, then soared by 170.6% to $581346.0 in 2024.
  • Its Gains from Sales and Divestitures stands at $581346.0 for Q4 2024, versus $214837.0 for Q4 2023 and $158546.0 for Q4 2022.